A clinical trial using whipworms to treat Crohn's disease was halted by a Coronado Biosciences partner because it did not reach response endpoints or remission goals. Coronado CEO Harlan Weisman said the results were not surprising because its own double-blind trial of parasitic worms for treating Crohn's also was not effective but said the company will continue to develop the therapy for autoimmune diseases.

Related Summaries